Yin C, Song C
Cells. 2025; 13(24.
PMID: 39768193
PMC: 11675013.
DOI: 10.3390/cells13242102.
Du X, He Y, Dong P, Yan C, Wei Y, Yao H
Transl Cancer Res. 2024; 13(9):4574-4592.
PMID: 39430815
PMC: 11483465.
DOI: 10.21037/tcr-24-191.
Rao J, Song C, Hao Y, Chen Z, Feng S, Xu S
Int J Biol Sci. 2024; 20(13):5363-5374.
PMID: 39430248
PMC: 11488587.
DOI: 10.7150/ijbs.96317.
Tang B, Zhu J, Shi Y, Wang Y, Zhang X, Chen B
Mol Cancer. 2024; 23(1):137.
PMID: 38970074
PMC: 11225310.
DOI: 10.1186/s12943-024-02049-0.
Funahashi N, Okada H, Kaneko R, Nio K, Yamashita T, Koshikawa N
Cancer Sci. 2024; 115(9):2972-2984.
PMID: 38951133
PMC: 11462950.
DOI: 10.1111/cas.16265.
Sphingosine kinase 2 and p62 regulation are determinants of sexual dimorphism in hepatocellular carcinoma.
Green C, Brown R, Uranbileg B, Weigel C, Saha S, Kurano M
Mol Metab. 2024; 86:101971.
PMID: 38925249
PMC: 11261290.
DOI: 10.1016/j.molmet.2024.101971.
Genetic screening of liver cancer: State of the art.
Peruhova M, Banova-Chakarova S, Miteva D, Velikova T
World J Hepatol. 2024; 16(5):716-730.
PMID: 38818292
PMC: 11135278.
DOI: 10.4254/wjh.v16.i5.716.
Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication.
Huang C, Awad M, Gal-Tanamy M, Yu M
Clin Mol Hepatol. 2024; 30(3):326-344.
PMID: 38665034
PMC: 11261227.
DOI: 10.3350/cmh.2024.0155.
Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential.
Sun M, Sun J, Sun W, Li X, Wang Z, Sun L
Front Pharmacol. 2024; 15:1369352.
PMID: 38595915
PMC: 11002155.
DOI: 10.3389/fphar.2024.1369352.
An integrated investigation of sulfotransferases (SULTs) in hepatocellular carcinoma and identification of the role of SULT2A1 on stemness.
Peng H, Feng K, Jia W, Li Y, Lv Q, Zhang Y
Apoptosis. 2024; 29(5-6):898-919.
PMID: 38411862
DOI: 10.1007/s10495-024-01938-5.
Lineage and ecology define liver tumor evolution in response to treatment.
Revsine M, Wang L, Forgues M, Behrens S, Craig A, Liu M
Cell Rep Med. 2024; 5(2):101394.
PMID: 38280378
PMC: 10897542.
DOI: 10.1016/j.xcrm.2024.101394.
HCV and HCC Tango-Deciphering the Intricate Dance of Disease: A Review Article.
Milosevic I, Todorovic N, Filipovic A, Simic J, Markovic M, Stevanovic O
Int J Mol Sci. 2023; 24(22).
PMID: 38003240
PMC: 10671156.
DOI: 10.3390/ijms242216048.
Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options.
Panneerselvam S, Wilson C, Kumar P, Abirami D, Pamarthi J, Reddy M
Cell Adh Migr. 2023; 17(1):1-21.
PMID: 37726886
PMC: 10512929.
DOI: 10.1080/19336918.2023.2258539.
An overview of mouse models of hepatocellular carcinoma.
Zheng H, Xue H, Yun W
Infect Agent Cancer. 2023; 18(1):49.
PMID: 37670307
PMC: 10481604.
DOI: 10.1186/s13027-023-00524-9.
Assessments of TP53 and CTNNB1 gene hotspot mutations in circulating tumour DNA of hepatitis B virus-induced hepatocellular carcinoma.
Kumar S, Nadda N, Quadri A, Kumar R, Paul S, Tanwar P
Front Genet. 2023; 14:1235260.
PMID: 37593116
PMC: 10429180.
DOI: 10.3389/fgene.2023.1235260.
Synthetic miR-26a mimics delivered by tumor exosomes repress hepatocellular carcinoma through downregulating lymphoid enhancer factor 1.
Hu J, Liu W, Zhang X, Shi G, Yang X, Zhou K
Hepatol Int. 2023; 17(5):1265-1278.
PMID: 37115456
DOI: 10.1007/s12072-023-10527-8.
An autophagy-inducing stapled peptide promotes c-MET degradation and overrides adaptive resistance to sorafenib in c-MET hepatocellular carcinoma.
Gao S, Li N, Zhang X, Chen J, Ko B, Zhao Y
Biochem Biophys Rep. 2022; 33:101412.
PMID: 36578529
PMC: 9791588.
DOI: 10.1016/j.bbrep.2022.101412.
SGLT-2 Inhibitors in Cancer Treatment-Mechanisms of Action and Emerging New Perspectives.
Dutka M, Bobinski R, Francuz T, Garczorz W, Zimmer K, Ilczak T
Cancers (Basel). 2022; 14(23).
PMID: 36497303
PMC: 9738342.
DOI: 10.3390/cancers14235811.
Advances in single-cell sequencing technology in the field of hepatocellular carcinoma.
Qin R, Zhao H, He Q, Li F, Li Y, Zhao H
Front Genet. 2022; 13:996890.
PMID: 36303541
PMC: 9592975.
DOI: 10.3389/fgene.2022.996890.
DNA methylation at hepatitis B virus integrants and flanking host mitochondrially encoded cytochrome C oxidase III.
Oikawa R, Watanabe Y, Yotsuyanagi H, Yamamoto H, Itoh F
Oncol Lett. 2022; 24(6):424.
PMID: 36284651
PMC: 9580253.
DOI: 10.3892/ol.2022.13544.